Drug Profile
XC 221
Alternative Names: Aterixen; XC-221; XC-221GILatest Information Update: 15 Nov 2023
Price :
$50
*
At a glance
- Originator Pharmenterprises
- Developer Pharmenterprises; RSV Therapeutics; Valenta Pharmaceuticals
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections; Influenza virus infections
- Phase II Respiratory tract infections
Most Recent Events
- 31 Oct 2023 Valenta Pharm plans a clinical trial for COVID-2019-infections (In volunteers) in Russia, in January 2024 (PO,Tablet) (NCT06096571)
- 04 May 2023 Valenta Pharm completes a phase-III clinical trials in Influenza virus infections in Russia (PO) (NCT05544916)
- 14 Nov 2022 RSV Therapeutics completes a phase III trial for COVID-2019 infections in Russia (NCT04940182)